Download PDF
Hamostaseologie 1996; 16(01): 1-5
DOI: 10.1055/s-0038-1656631
Übersichtsarbeiten/Review Articles
Schattauer GmbH

Eigenschaften und Analytik von Heparinoiden

R. Malsch
1   1. Medizinische Klinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. med. D. L. Heene)
,
J. Harenberg
1   1. Medizinische Klinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. med. D. L. Heene)
› Author AffiliationsDie Arbeit wurde unterstützt von der Deutschen Forschungsgemeinschaft Ha 1164/3-2 und dem Forschungsprojekt der Fakultät für klinische Medizin Mannheim.
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Heparinoide umfassen strukturell und pharmakologisch unterschiedliche Substanzen mit Glykanstruktur. Als wichtigste Vertreter dieser Substanzklasse sind Dermatansulfat, Pentosanpolysulfat, Aprosulat und Orgaran anzusehen. In dieser Übersicht werden die chemische Struktur, die pharmakologischen Wirkungen dieser Stoffe und ihre Analytik besprochen. Sie wirken unterschiedlich auf die Gerinnungskaskade ein und inhibieren Thrombin. Zu ihrem Vergleich sind daher globale Gerinnungsteste notwendig. Ihre genaue pharmakologische Wirkung läßt sich durch spezifische Testsysteme bestimmen. Die chemische Bestimmung ihrer Struktur und Masse erfolgt über Elementaranalyse, spektroskopische, chromatographische und elektrophoretische Methoden.

Schlüsselwörter

Heparinoide - Pharmakologie - Analytik - Dermatansulfat - Pentosanpolysulfat
 

  • LITERATUR

  • 1 Fareed J, Hoppensteadt D, Walenga JM. et al. Molecular and functional heterogeneity in dermatan preparations. Semin Thromb Haemost 1991; 17 (Suppl. 02) 174-80
    PubMedGoogle Scholar
  • 2 Malsch R, Harenberg J. Considerations about the correct nomenclature of glycosami-noglycans. Thromb Haemost 1993; 18: 718-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Dol F, Petitou M, Lormeau JC. et al. Pharmacologic properties of a low molecular weight dermatan sulfate: Comparison with unfractionated dermatan sulfate. J Clin Med 1990; 115: 541-8
    PubMedGoogle Scholar
  • 4 Tollefsen DM, Pestka CA, Monafo WJ, Monafo J. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6
    PubMedGoogle Scholar
  • 5 Ofosu FA, Fernandez F, Gauthia D, Bu-chanan M. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic anticoagulant effects of heparin and dermatan sulphate. Semin Thromb Haemost 1985; 11: 1333-7
    PubMedGoogle Scholar
  • 6 Fernandez J, Van Ryn, Ofosu FA. et al. The haemorrhagic and antithrombotic effects of dermatan sulfate. Br J Haematol 1986; 64: 309-17
    CrossrefPubMedGoogle Scholar
  • 7 Hoppensteadt D, Walenga JM, Farred J. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Thromb Res 1990; 60: 191-200
    CrossrefPubMedGoogle Scholar
  • 8 Maffrand JP, Hebbert JM, Bernat A. et al. Experimental and clinical pharmacology of pentosan polysulfate. Semin Thromb Haemost 1991; 17 (Suppl. 02) 186-98
    PubMedGoogle Scholar
  • 9 Bode V, Franz G. Heparinoide: Ihre anti-koagulierende Wirkung. DAZ 1989; 129: 672-5
    PubMedGoogle Scholar
  • 10 Zugmaier G, Lippman ME, Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 1992; 84 (22) 1716-24
    CrossrefPubMedGoogle Scholar
  • 11 Hakim A. Activité et tolerance de l'he-moclar dans la prevention des thromboses veineuses profondes post-operatoires en Phlebologie. Etude sur 3000 cas. Angieolo-gie 1987; 39 (06) 187-9
    PubMedGoogle Scholar
  • 12 Claude PH, Pescio M. Essai comparatif sur la prevention de la maladie thromboembo-lique post operatoire par le polysulfate de pentosane et heparinate de calcium. Gazette Medicale 1984; 91: 136-8
    PubMedGoogle Scholar
  • 13 Raake W, Klause RJ, Elling H, Meinetsber-gern E. Anticoagulant and antithrombotic properties of synthetic sulfated bis-lactobio-nic acid amides. Thromb Res 1988; 56: 719-30
    PubMedGoogle Scholar
  • 14 Fareed J, Coker S, Iqbal O. et al. Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (apro-sulate in primates). Semin Thromb Haemost 1991; 17 (Suppl. 02) 147-52
    PubMedGoogle Scholar
  • 15 Hoppensteadt D, Walenga JM, Fareed J. Protamine sulfate neutralisation of lactobionic acid amides. Semin Thromb Haemost 1991; 17 (Suppl. 02) 153-7
    PubMedGoogle Scholar
  • 16 Meuleman DG. Orgaran (Org 10172): Its pharmacological profile in experimental models. Haemostasis 1992; 22 (02) 58-65
    PubMedGoogle Scholar
  • 17 Turpie AG. Orgaran in the prevention of deep vein thrombosis in stroke patients. Haemostasis 1992; 22 (02) 92-8
    PubMedGoogle Scholar
  • 18 Greinacher A, Alban S, Dummel V. et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin associated thrombocytopenia. Thromb Haemostas 1995; 74: 886-92
    PubMedGoogle Scholar
  • 19 Danhof M, de-Boer A, Magnani HN, Stiekema JC. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992; 22 (02) 73-84
    PubMedGoogle Scholar
  • 20 Harenberg J, Giese C, Knödler A, Zimmermann R. Comparative study of a new one-stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 1989; 19: 21-5
    PubMedGoogle Scholar
  • 21 Harenberg J, Giese C, Knödler A, Zimmermann R. Antifaktor-Xa-Gerinnungsmethode für Heparin und niedermolekulare Heparine. Ärztl Lab 1986; 32: 181-2
    PubMedGoogle Scholar
  • 22 Harenberg J. Modified anti-factor Xa chro-mogenic substrate assay for heparin and low molecular weight heparins. Ärztl Lab 1987; 33: 39-41
    PubMedGoogle Scholar
  • 23 Bitter T, Muir HM. A modified uronic acid carbazole reaction. Anal Biochem 1962; 4: 330-4
    CrossrefPubMedGoogle Scholar
  • 24 Smith PK, Mallia AK, Hermamson GT. Colorimetric method for the assay of heparin content in immobilized preparations. Anal Biochem 1980; 09: 466-73
    PubMedGoogle Scholar
  • 25 Mascellani G, Rasconi A, Brugnoli E, Bian-chini P. Potenziometria applicata alla carat-terizzazione ed analisi polisaccaridi di uso farmaceutico. Il Farmaco 1988; 5: 165-75
    PubMedGoogle Scholar
  • 26 Harenberg J, de Vries JX. Characterization of heparins by high-performance size exclusion chromatography. J Chromatogr 1983; 262: 287-92
    PubMedGoogle Scholar
  • 27 Rice KG, Rottink MK, Linhardt RJ. Fractionation of heparin-derived oligosaccharides by gradient Polyacrylamide gel electrophoresis. Biochem J 1987; 244: 515-22
    CrossrefPubMedGoogle Scholar
  • 28 Rice KG, Kim YS, Grant AC. et al. Highperformance liquid chromatographic separation of heparin-derived oligosaccharides. Anal Biochem 1985; 150: 325-31
    CrossrefPubMedGoogle Scholar
  • 29 Guo Y, Corad HE. Analysis of oligosaccharides from heparin by reversed-phase ion-paring high-performance liquid chromatography. Anal Biochem 1988; 168: 54-62
    CrossrefPubMedGoogle Scholar
  • 30 Ampofo SA, Wang HM, Linhardt RJ. Di-saccharide compositional analysis of heparin and heparan sulfate. Anal Biochem 1991; 199: 249-55
    CrossrefPubMedGoogle Scholar
  • 31 Longas MO, Breitwieser KO. Sulfate composition of glycosaminoglycans determined by infrared spectroscopy. Anal Biochem 1991; 192: 193-6
    CrossrefPubMedGoogle Scholar
  • 32 Alban S, Franz G. Gas liquid-mass spectrometry analysis of anticoagulant active curd-Ian sulfates. Semin Thromb Haemostas 1994; 20 (02) 152-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Gettins P, Horne AP. One and two-dimensional 13C-NMR characterization of two series of oligosacharides derived from porcine intestinal heparin by degradation with heparinase. Carbohydr Res 1992; 223: 81-98
    CrossrefPubMedGoogle Scholar